Penumbra, Inc. (PEN)
Market Cap | 11.18B |
Revenue (ttm) | 1.24B |
Net Income (ttm) | 42.23M |
Shares Out | 38.73M |
EPS (ttm) | 1.08 |
PE Ratio | 267.83 |
Forward PE | 72.03 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 300,562 |
Open | 290.02 |
Previous Close | 289.25 |
Day's Range | 288.32 - 294.28 |
52-Week Range | 148.00 - 310.00 |
Beta | 0.53 |
Analysts | Strong Buy |
Price Target | 299.73 (+3.81%) |
Earnings Date | Apr 23, 2025 |
About PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDW... [Read more]
Financial Performance
In 2024, Penumbra's revenue was $1.19 billion, an increase of 12.86% compared to the previous year's $1.06 billion. Earnings were $14.01 million, a decrease of -84.59%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for PEN stock is "Strong Buy." The 12-month stock price forecast is $299.73, which is an increase of 3.81% from the latest price.
News

Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference
ALAMEDA, Calif. , April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesd...

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopha...

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst
Penumbra Inc PEN stock is trading higher after the company reported better-than-expected first-quarter 2025 earnings and reaffirmed the 2025 forecast.

Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN) Q1 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Cecilia Furlong - Business Development & IR Adam Elsesser - Chairman & CEO Maggie Yuen - CFO ...

Penumbra, Inc. Reports First Quarter 2025 Financial Results
ALAMEDA, Calif. , April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025.

Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025
ALAMEDA, Calif. , April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market clos...

Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits
ALAMEDA, Calif. , April 2, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data pre...

Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors
ALAMEDA, Calif. , Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has noti...

Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook
Penumbra Inc PEN is trading higher after the company reported better-than-expected fourth-quarter earnings.

Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - ...

Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
ALAMEDA, Calif. , Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended Decemb...

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025
ALAMEDA, Calif. , Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 af...

Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ALAMEDA, Calif. , Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P.

Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst
Shares of Penumbra Inc PEN recovered slightly in early trading on Tuesday, after a week of correction.

Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
ALAMEDA, Calif. , Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on We...

New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options
Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum th...

Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - C...

Penumbra, Inc. Reports Third Quarter 2024 Financial Results
ALAMEDA, Calif. , Oct. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024.

Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke
ALAMEDA, Calif. , Oct. 14, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients ...

Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024
ALAMEDA, Calif. , Oct. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2024 after market close...

Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash™ 2.0 and Lightning Bolt™ 7 - in Europe
Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quickly Lightni...

Penumbra, Inc. to Present at the Baird Global Healthcare Conference
ALAMEDA, Calif. , Aug. 27, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Baird Global Healthcare Conference on Tuesday, Septem...

Penumbra, Inc. to Present at the Wells Fargo Healthcare Conference
ALAMEDA, Calif. , Aug. 21, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday, Septe...

Penumbra: Growth In Its Thrombectomy Portfolio Should Lead To Strong Earnings
Penumbra is continuing to take share with its new CAVT devices against its closest competition in the VTE space. PEN reduced guidance after Q2 earnings, but the market took it in stride, with difficul...

Penumbra, Inc. Announces $200 Million Share Repurchase Authorization
To Include $100 Million Accelerated Share Repurchase ALAMEDA, Calif. , Aug. 13, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced that its Boar...